BlossomHill Therapeutics advances pan-KRAS inhibitor BH-501284 toward Q1 2027 IND filing
The company said preclinical data on BH-501284 were presented at the AACR pancreatic cancer conference Sept. 25-28, 2026.
The company said preclinical data on BH-501284 were presented at the AACR pancreatic cancer conference Sept. 25-28, 2026.